Journal of neurosurgery · 2002 · 52 citations · 34 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCancer VaccinesCytokine-based TherapyDendritic Cell BiologyImmunotherapy For Brain TumorsTherapeutic VaccinesAntitumor Cytokine ResponsesAntitumor Immune ActivationApoptotic Signaling In Immune CellsDendritic Cell-t Cell InteractionTherapeutic Cancer ImmunizationTumor Antigen Vaccines
OBJECT: The authors evaluated dendritic cell (DC)-based immunotherapy for malignant brain tumor to improve its therapeutic efficacy. METHODS: Dendritic cells were isolated from bone marrow and pulsed with phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector GCsap-interleukin (IL)-12, and SFV-IL-12, respectively, to treat mice bearing brain tumors of the B16 cell line. The results indicated that therapeutic immunization with DCs pulsed with SFV-IL-12 prolonged the survival of mice with established tumors. Semliki Forest virus induced apoptosis in DCs, which in turn facilitated the uptake of apoptotic cells by other DCs, thus providing a potential mechanism for enhanced immunogenicity. CONCLUSIONS: Therapy with DCs that have been pulsed with SFV-mediated IL-12 may be an excellent step in the development of new cancer vaccines. Intratumorally injected DCs that have been transiently transduced with IL-12 do not require pulsing of a source of tumor antigens to induce tumor regression.
34
Requirement for V <sub>α</sub> 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Junqing Cui, Tahiro Shin, Tetsu Kawano et al. · Science · 1997 · 1.2K citations